Cargando…

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma

BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by seque...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yubo, Yao, Jingwei, Wen, Meiling, Liu, Xiong, Huang, Jialu, Zhang, Minghui, Zhang, Yu, Lv, Yufan, Xie, Zhuoyi, Zuo, JianHong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121877/
https://www.ncbi.nlm.nih.gov/pubmed/35602894
http://dx.doi.org/10.7717/peerj.13473
_version_ 1784711235439165440
author Ding, Yubo
Yao, Jingwei
Wen, Meiling
Liu, Xiong
Huang, Jialu
Zhang, Minghui
Zhang, Yu
Lv, Yufan
Xie, Zhuoyi
Zuo, JianHong
author_facet Ding, Yubo
Yao, Jingwei
Wen, Meiling
Liu, Xiong
Huang, Jialu
Zhang, Minghui
Zhang, Yu
Lv, Yufan
Xie, Zhuoyi
Zuo, JianHong
author_sort Ding, Yubo
collection PubMed
description BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by sequencing. METHODS: We used next-generation targeted sequencing technology to identify mutations in patients with liver cancer. The ctDNA from 10 patients with hepatocellular carcinoma (including eight cases of primary hepatocellular carcinoma and two cases of secondary hepatocellular carcinoma) was sequenced. We used SAMtools to detect and screen single nucleotide polymorphisms (SNPs) and insertion deletion mutations (INDELs) and ANNOVAR to annotate the structure and function of the detected mutations. Screening of pathogenic and possible pathogenic genes was performed using American College of Medical Genetics and Genomics (ACMG) guidelines. GO analysis and KEGG analysis of pathogenic and possible pathogenic genes were performed using the DAVID database, and protein–protein interaction network analysis of pathogenic and possible pathogenic genes was performed using the STRING database. Then, the Kaplan–Meier plotter database, GEPIA database and HPA database were used to analyse the relationship between pathogenic and possible pathogenic genes and patients with liver cancer. RESULTS: Targeted capture and deep sequencing of 560 cancer-related genes in 10 liver cancer ctDNA samples revealed 8,950 single nucleotide variation (SNV) mutations and 70 INDELS. The most commonly mutated gene was PDE4DIP, followed by SYNE1, KMT2C, PKHD1 and FN1. We compared these results to the COSMIC database and determined that ctDNA could be used for sequencing. According to the ACMG guidelines, we identified 54 pathogenic and possible pathogenic mutations in 39 genes in exons and splice regions of 10 HCC patients and performed GO analysis, KEGG analysis, and PPI network analysis. Through further analysis, four genes significantly related to the prognosis of liver cancer were identified. CONCLUSION: In this study, our findings indicate that ctDNA can be used for sequencing. Our results provide some molecular data for the mapping of genetic variation in Chinese patients with liver cancer, which enriches the understanding of HCC pathogenesis and provides new ideas for the diagnosis and prognosis of HCC patients.
format Online
Article
Text
id pubmed-9121877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-91218772022-05-21 The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma Ding, Yubo Yao, Jingwei Wen, Meiling Liu, Xiong Huang, Jialu Zhang, Minghui Zhang, Yu Lv, Yufan Xie, Zhuoyi Zuo, JianHong PeerJ Bioinformatics BACKGROUND: The genome map of hepatocellular carcinoma (HCC) is complex. In order to explore whether circulating tumor cell DNA (ctDNA) can be used as the basis for sequencing and use ctDNA to find tumor related biomarkers, we analyzed the mutant genes of ctDNA in patients with liver cancer by sequencing. METHODS: We used next-generation targeted sequencing technology to identify mutations in patients with liver cancer. The ctDNA from 10 patients with hepatocellular carcinoma (including eight cases of primary hepatocellular carcinoma and two cases of secondary hepatocellular carcinoma) was sequenced. We used SAMtools to detect and screen single nucleotide polymorphisms (SNPs) and insertion deletion mutations (INDELs) and ANNOVAR to annotate the structure and function of the detected mutations. Screening of pathogenic and possible pathogenic genes was performed using American College of Medical Genetics and Genomics (ACMG) guidelines. GO analysis and KEGG analysis of pathogenic and possible pathogenic genes were performed using the DAVID database, and protein–protein interaction network analysis of pathogenic and possible pathogenic genes was performed using the STRING database. Then, the Kaplan–Meier plotter database, GEPIA database and HPA database were used to analyse the relationship between pathogenic and possible pathogenic genes and patients with liver cancer. RESULTS: Targeted capture and deep sequencing of 560 cancer-related genes in 10 liver cancer ctDNA samples revealed 8,950 single nucleotide variation (SNV) mutations and 70 INDELS. The most commonly mutated gene was PDE4DIP, followed by SYNE1, KMT2C, PKHD1 and FN1. We compared these results to the COSMIC database and determined that ctDNA could be used for sequencing. According to the ACMG guidelines, we identified 54 pathogenic and possible pathogenic mutations in 39 genes in exons and splice regions of 10 HCC patients and performed GO analysis, KEGG analysis, and PPI network analysis. Through further analysis, four genes significantly related to the prognosis of liver cancer were identified. CONCLUSION: In this study, our findings indicate that ctDNA can be used for sequencing. Our results provide some molecular data for the mapping of genetic variation in Chinese patients with liver cancer, which enriches the understanding of HCC pathogenesis and provides new ideas for the diagnosis and prognosis of HCC patients. PeerJ Inc. 2022-05-17 /pmc/articles/PMC9121877/ /pubmed/35602894 http://dx.doi.org/10.7717/peerj.13473 Text en ©2022 Ding et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Bioinformatics
Ding, Yubo
Yao, Jingwei
Wen, Meiling
Liu, Xiong
Huang, Jialu
Zhang, Minghui
Zhang, Yu
Lv, Yufan
Xie, Zhuoyi
Zuo, JianHong
The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title_full The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title_fullStr The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title_full_unstemmed The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title_short The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
title_sort potential, analysis and prospect of ctdna sequencing in hepatocellular carcinoma
topic Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121877/
https://www.ncbi.nlm.nih.gov/pubmed/35602894
http://dx.doi.org/10.7717/peerj.13473
work_keys_str_mv AT dingyubo thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT yaojingwei thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT wenmeiling thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT liuxiong thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT huangjialu thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zhangminghui thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zhangyu thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT lvyufan thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT xiezhuoyi thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zuojianhong thepotentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT dingyubo potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT yaojingwei potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT wenmeiling potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT liuxiong potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT huangjialu potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zhangminghui potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zhangyu potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT lvyufan potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT xiezhuoyi potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma
AT zuojianhong potentialanalysisandprospectofctdnasequencinginhepatocellularcarcinoma